Charlie Munger Shares His Blunt Views Of US Healthcare, Labeling It A 'Global Embarrassment' And Comparing It To Botox Treatment For Women Who Are 'Hopeless'

Berkshire Hathaway Inc. Vice Chairman Charlie Munger has consistently been a vocal critic of the American healthcare system, dissecting its shortcomings across both economic and ethical dimensions. 

In a recent CNBC video, he described the U.S. healthcare industry as a "global embarrassment," blasting its inefficiency and high costs compared to countries like Singapore, which delivers similar services for a fraction of the price. 

This was a reiteration of his past critiques, including the accusation that some medical providers "artificially prolong death so they can make more money," an act he deemed "deeply immoral." His longtime business partner Warren Buffett has also voiced concern, describing healthcare spending as a "tapeworm on the economic system."

Don’t Miss:

• Until 2016 it was illegal for retail investors to invest in high-growth startups. Thanks to changes in federal law, this Kevin O’Leary-backed startup lets you become a venture capitalist with $100.
• With returns as high as 300%, it’s no wonder this asset is the investment choice of many billionaires. Uncover the secret.

Munger's sharp critique hasn't been confined to recent years. Speaking to University of Michigan students in 2010, he expressed a nuanced view on healthcare spending. 

"In an aging affluent civilization where GDP (gross domestic product) rises at 2% or 3% per year per capita, I don't think it matters at all if we spent 20% of GDP on healthcare," he said.

But his concern was not just the total expenditure; it was also the quality and necessity of the services that make up that spending. Using Botox as an example, he argued that a chunk of healthcare spending was on essentially futile treatments — "like Botox for women for whom intervention is hopeless."

His focus is not just on the amount of money allocated but also on whether those funds are used for truly beneficial interventions. Munger also brings up the subject of public responsibility and dependence on government aid. He cautions against a society that turns to the government to solve every problem and says the balance between individual and collective responsibility in healthcare must be considered.

Trending: Airbnb was worth $47 billion at IPO. This startup is automating the trillion-dollar hospitality market.

For the average American, who unlike Munger can't afford world-class healthcare out-of-pocket, the implications are profound. Navigating this complex and often flawed system requires personal advocacy and due diligence, be it in searching for affordable treatment options or focusing on preventive measures.

Whether considering the sheer economics or the ethical implications, Munger's multifaceted critique offers a compelling framework for rethinking healthcare spending in America, underscoring the need for changes at both systemic and individual levels.

For anyone who shares Munger's concerns about the inefficiencies and ethical dilemmas in American healthcare, there are ways to contribute to change. One approach is to invest in innovative companies like iRemedy. iRemedy is working to revolutionize the medical supply industry, which suffers from high costs, supply shortages and a poor customer experience. 

With $52 million in revenue in 2022 and a client base that includes notable organizations like Mayo Clinic, Johns Hopkins Medicine and the American Red Cross, iRemedy aims to fix the broken medical supply chain through artificial intelligence (AI)-driven solutions.

iRemedy's transparent pricing, easy ordering and constant supply monitoring are the antithesis to the issues Munger points out in the American healthcare system. By investing in companies with these sorts of innovative solutions, everyday people can take part in tackling the very healthcare issues that industry leaders like Munger criticize. 

In a system that's widely seen as flawed, supporting new approaches could be a step toward much-needed reform.

Read Next:

• Join the ranks of investors like Bill Gates and Mark Cuban by tapping into early-stage startups. Get the inside scoop on this innovative startup here.
• Elon Musk and Richard Branson explore early-stage startups. Don’t miss out on this exciting investment opportunity just like these visionaries.